source
- FDA approves relacorilant with nab-paclitaxel for platinum-resistant ovarian cancerThe FDA has granted approval for the combination of relacorilant and nab-paclitaxel to treat adult patients with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer…
- Angelini to acquire Catalyst Pharmaceuticals for $4.1 billion, adding rare CNS drug portfolioAngelini Pharma announced it will purchase Catalyst Pharmaceuticals in a cash transaction valued at about $4.1 billion. The agreement pays $31.50 per Catalyst share, representing a 21% premium to…